KBIO
KaloBios Pharmaceuticals, Inc.
Other OTC
People also watch:CANFSPHSPBMDMCURAEZS
3.91-0.22 (-5.32%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close4.13
Open4.20
Bid0.00 x
Ask0.00 x
52wk Range3.69 - 5.21
Day's Range3.86 - 4.20
Volume2,788
Avg Vol (3m)31,969
As of 12:36 PM EDT. Other OTC Delayed Price. Market open.
  • American City Business Journals7 days ago

    Who made lots of money from this biotech bankruptcy? Hint: It wasn't Martin Shkreli

    KaloBios Pharmaceuticals Inc.'s quick but complex trip through Chapter 11 bankruptcy reorganization translated into big paydays for law firms and other advisors that shepherded the Brisbane company through the process. Four firms — two law firms, a financial advisor and an administrative advisor — billed more than $4 million for fees and reimbursable expenses racked up in the name of helping KaloBios (KBIO) get up on the good foot after missteps before and during the tumultuous tenure of drug industry bad boy Martin Shkreli. In all, KaloBios' bankruptcy co-counsel, Hogan Lovells US LLP and Morris, Nichols, Arsht and Tunnell LLP, through Tuesday submitted more than $3.9 million in fees and expenses.

  • Forbes20 days ago

    Shkreli Is Out As Shareholder And Influencer Of KaloBios -- Well, Almost

    KaloBios just took another step towards ridding itself of Martin Shkreli, but the biotech company is still facing plenty of challenges.